Page 310 - Read Online

Qureshy et al. J Cancer Metastasis Treat 2020;6:27 I http://dx.doi.org/10.20517/2394-4722.2020.58 Page 15 of 18

78. Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, et al. Cancer-associated fibroblasts share characteristics and protumorigenic
activity with mesenchymal stromal cells. Cancer Res 2017;77:5142-57.
79. Hadjidaniel MD, Muthugounder S, Hung LT, Sheard MA, Shirinbak S, et al. Tumor-associated macrophages promote neuroblastoma via
STAT3 phosphorylation and up-regulation of c-MYC. Oncotarget 2017;8:91516-29.
80. Mohrherr J, Haber M, Breitenecker K, Aigner P, Moritsch S, et al. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma
progression. Int J Cancer 2019;145:3376-88.
81. Hu Y, Hong Y, Xu Y, Liu P, Guo DH, et al. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in
nonsmall-cell lung cancer NSCLC. Apoptosis 2014;19:1627-36.
82. Dolatabadi S, Jonasson E, Lindén M, Fereydouni B, Bäcksten K, et al. JAK-STAT signalling controls cancer stem cell properties
including chemotherapy resistance in myxoid liposarcoma. Int J Cancer 2019;145:435-49.
83. McLean K, Tan L, Bolland DE, Coffman LG, Peterson LF, et al. Leukemia inhibitory factor functions in parallel with interleukin-6 to
promote ovarian cancer growth. Oncogene 2019;38:1576-84.
84. Reeves PM, Abbaslou MA, Kools FRW, Vutipongsatorn K, Tong X, et al. Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol,
limits tumor growth and improves survival in immune competent mice. Oncotarget 2017;8:94040-53.
85. Escobar-Zarate D, Liu YP, Suksanpaisan L, Russell SJ, Peng KW. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2
inhibitors. Cancer Gene Ther 2013;20:582-9.
86. Cataldi M, Shah NR, Felt SA, Grdzelishvili VZ. Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus
through a novel activity of IKK inhibitor TPCA-1. Virology 2015;485:340-54.
87. Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, et al. Constitutive interferon pathway activation in tumors as an
efficacy determinant following oncolytic virotherapy. J Natl Cancer Inst 2018;110:1123-32.
88. Patel MR, Dash A, Jacobson BA, Ji Y, Baumann D, et al. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in
nonsmall cell lung cancer models. Cancer Gene Ther 2019;26:411-8.
89. Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in
combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol
2015;33:4039-47.
90. Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after
disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs 2018;36:683-95.
91. O’Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, et al. A randomized, double-blind, phase 2 study of ruxolitinib or
placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a
marker of systemic inflammation. Breast Cancer Res Treat 2018;170:547-57.
92. Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, et al. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in
patients with metastatic triple-negative breast cancer. NPJ Breast Cancer 2018;4:10.
93. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
94. Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, et al. Randomized, double-blind, phase two study of ruxolitinib
plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Med 2018;7:5382-93.
95. Giaccone G, Sanborn RE, Waqar SN, Martinez-Marti A, Ponce S, et al. A placebo-controlled phase II study of ruxolitinib in combination
with pemetrexed and cisplatin for first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer and systemic
inflammation. Clin Lung Cancer 2018;19:e567-74.
96. Park JS, Hong MH, Chun YJ, Kim HR, Cho BC. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC
with progression on EGFR-TKIs. Lung Cancer 2019;134:46-51.
97. Yu HA, Perez L, Chang Q, Gao SP, Kris MG, et al. A phase 1/2 trial of Ruxolitinib and Erlotinib in patients with EGFR-mutant lung
adenocarcinomas with acquired resistance to Erlotinib. J Thoracic Oncol 2017;12:102-9.
98. Bauer TM, Rpatel M, Forero-Torres A, George TJ, Assad A, et al. Aphase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in
patients with advanced solid tumors. Onco Targets Ther 2018;11:2399-407.
99. Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N
Engl J Med 2017;376:1723-36.
100. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med
2014;370:2377-86.
101. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with
methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind,
head-to-head, randomised controlled trial. Lancet 2017;390:457-68.
102. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid
arthritis. N Engl J Med 2012;367:495-507.
103. Lapeire L, Hendrix A, Lambein K, Van Bockstal M, Braems G, et al. Cancer-associated adipose tissue promotes breast cancer progression
by paracrine oncostatin M and Jak/STAT3 signaling. Cancer Res 2014;74:6806-19.
104. Seol MA, Kim JH, Oh K, Kim G, Seo MW, et al. Interleukin-7 Contributes to the invasiveness of prostate cancer cells by promoting
epithelial-mesenchymal transition. Sci Rep 2019;9:6917.
105. McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, et al. Therapeutic potential of AZD1480 for the treatment of human
glioblastoma. Mol Cancer Ther 2011;10:2384-93. Page 16 of 18 Qureshy et al. J Cancer Metastasis Treat 2020;6:27 I http://dx.doi.